Prosecution Insights
Last updated: April 19, 2026

Myriad Genetics Inc.

8 pending office actions

Portfolio Summary

8
Total Pending OAs
3
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19088496 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY HANEY, AMANDA MARIE 1682 Non-Final OA Mar 24, 2025
19088442 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY WHALEY, PABLO S 3619 Final Rejection Mar 24, 2025
19087361 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY JOHANNSEN, DIANA B 1682 Non-Final OA Mar 21, 2025
18076279 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY IN BREAST CANCER SUBTYPES HOPPE, EMMA RUTH 1683 Non-Final OA Dec 06, 2022
17678357 GENE SIGNATURES FOR CANCER PROGNOSIS HORLICK, KENNETH R 1681 Final Rejection Feb 23, 2022
17499284 METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY WHALEY, PABLO S 3619 Final Rejection Oct 12, 2021
17353279 METHODS AND MATERIALS FOR ASSESSING HOMOLOGOUS RECOMBINATION DEFICIENCY HANEY, AMANDA MARIE 1682 Non-Final OA Jun 21, 2021
16664216 CANCER BIOMARKERS LIN, JERRY 1685 Non-Final OA Oct 25, 2019

Managing Myriad Genetics Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month